According to a univariate analysis, tumor progression was significantly related to both melanoma thickness and COX2 immunoreactivity, respectively (P = .03; Table 3); that is, expression of COX2 was associated with shorter progression-free survival (P = .03; Figure 3). The gene discussed is PTGS2; the disease is melanoma.